Transcenta Starts US Arm of US-China Bi-specific PD-1 Trial for Solid Tumors

Transcenta Holding, a Suzhou biopharma, was approved to start a US Phase I trial of its bi-functional anti-PD-L1/TGF-β antibody in patients with solid tumors. Transcenta plans to add a China arm to the trial when China approves its already-filed IND for the bi-specific candidate. Previously, the company started Phase II trials of its anti-PD-L1 candidate as a stand-alone product in China and the US . TST005 consists of a high affinity PD-L1 antibody fused with an engineered TGF-β Receptor (transforming growth factor -β) Type II protein in its C-terminal. More details.... Share this with colleagues: // //